

# Alembic Pharma

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	ALPM IN
Equity Shares (m)	197
M.Cap.(INRb)/(USDb)	158.6 / 1.8
52-Week Range (INR)	1108 / 725
1, 6, 12 Rel. Per (%)	-1/-19/-17
12M Avg Val (INR M)	231

## Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	73.9	81.1	89.8
EBITDA	12.0	14.0	16.7
Adj. PAT	6.9	8.6	10.4
EBIT Margin (%)	12.1	13.0	14.3
Cons. Adj. EPS (INR)	35.1	43.5	52.9
EPS Gr. (%)	20.4	24.1	21.6
BV/Sh. (INR)	291.3	329.2	376.5

## Ratios

Net D:E	0.2	0.1	0.1
RoE (%)	12.6	13.9	14.9
RoCE (%)	11.3	12.7	13.6
Payout (%)	18.1	13.8	11.4

## Valuations

P/E (x)	22.9	18.4	15.2
EV/EBITDA (x)	16.7	14.1	11.6
Div. Yield (%)	0.7	0.7	0.7
FCF Yield (%)	3.3	3.3	4.4
EV/Sales (x)	2.7	2.4	2.2

## Shareholding pattern (%)

As of	Dec-25	Sep-25	Dec-24
Promoter	69.7	69.7	69.6
DII	16.2	16.3	16.1
FII	4.2	4.1	4.2
Others	9.9	9.9	10.2

FII includes depository receipts

**CMP: INR807 TP: INR860 (+7%) Neutral**

**Ex-US and Animal Health perform, while DF and US lag**

## Gearing up for the branded product launch in the US

- Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic formulation (DF) and US sales.
- Within DF, ALPM witnessed muted growth in acute as well as specialty therapies. The company is implementing measures to improve the growth prospects of the DF segment.
- ALPM has retained the growth momentum in the animal health business, with a majority of the business coming from feed supplements and tonics.
- In addition to the generics portfolio in the US, ALPM would be introducing a branded product in the US from 4QFY26.
- ALPM exhibited strong growth in the non-US export business for the fourth consecutive quarter.
- We largely maintain our estimates for FY26/FY27/FY28.
- While there have been considerable investments in the US generics space in terms of R&D as well as manufacturing capacity, it has yet to be reflected in meaningful revenue growth in this segment. The domestic formulation business is expected to gradually grow-in-line with the industry. Considering these factors and valuations adequately factoring in the earnings upside, we **reiterate our Neutral rating** with a TP of INR860.

## Segmental mix impact offset by operating leverage for the quarter

- ALPM's sales grew 11% YoY to INR18.8b (our est: INR 18.5b).
- Gross margin contracted 220bp YoY to 71.8%.
- EBITDA margin expanded 30bp YoY to 15.6%, driven by lower employee expenses (down 40bp YoY as % of sales) and other expenses (down 400bp YoY as % of sales). This was partly offset by higher R&D expenses (+180bp YoY as % of sales).
- Consequently, EBITDA grew 13% YoY to INR2.9b (our est: INR3b).
- A one-time exceptional charge of INR422m was recognized following the revision in labor code provisions.
- Adj. PAT grew 21% YoY to INR1.7b. (our est: INR1.8b)
- For 9MFY26, ALPM delivered 12%/21%/19% YoY growth in revenue/EBITDA/PAT to INR55b/INR8.9b/INR4.9b.

## DF/US/API drags overall YoY revenue growth

- The US generics sales grew 6% YoY to INR5.5b (29% of sales).
- Ex-US generic export sales grew 36% YoY to INR4.1b (22% of sales).
- Domestic formulation (DF) sales grew 6% YoY to INR6.5b (35% of sales).
- API sales grew 2% YoY to INR2.6b (14% of sales).

**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Research Analyst: Vipul Mehta** (Vipul.Mehta@MotilalOswal.com), **Eshita Jain** (Eshita.Jain@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

### Key highlights from the management commentary

- Considering the efforts implemented, ALPM indicated that growth would be in line with the industry from 1QFY27 onwards in the DF segment.
- ALPM is on track to launch Pivya in the US in 4QFY26. This launch will expand ALPM's footprint in branded drugs in the US.
- ALPM indicated 10-15% YoY growth in the US business over the next 12-15M.
- ALPM does not intend to add MRs over the near term for the DF market.

### Quarterly perf. (Consol.)

(INR m)

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	vs Est
<b>Net Sales</b>	<b>15,617</b>	<b>16,480</b>	<b>16,927</b>	<b>17,696</b>	<b>17,107</b>	<b>19,102</b>	<b>18,763</b>	<b>18,919</b>	<b>66,721</b>	<b>73,891</b>	<b>18,509</b>	<b>1.4%</b>
YoY Change (%)	5.1	3.3	3.8	16.7	9.5	15.9	10.8	6.9	7.1	10.7	9.3	
Total Expenditure	13,249	14,087	14,325	14,977	14,294	15,945	15,828	15,798	56,639	61,864	15,474	
<b>EBITDA</b>	<b>2,368</b>	<b>2,393</b>	<b>2,602</b>	<b>2,719</b>	<b>2,813</b>	<b>3,157</b>	<b>2,935</b>	<b>3,122</b>	<b>10,082</b>	<b>12,027</b>	<b>3,035</b>	<b>-3.3%</b>
YoY Change (%)	19.2	14.9	-2.4	4.6	18.8	31.9	12.8	14.8	8.1	19.3	16.7	
Margins (%)	15.2	14.5	15.4	15.4	16.4	16.5	15.6	16.5	15.1	16.3	16.4	
Depreciation	690	705	700	690	738	761	801	812	2,786	3,112	798	
<b>EBIT</b>	<b>1,678</b>	<b>1,688</b>	<b>1,902</b>	<b>2,029</b>	<b>2,075</b>	<b>2,396</b>	<b>2,134</b>	<b>2,310</b>	<b>7,297</b>	<b>8,915</b>	<b>2,238</b>	
YoY Change (%)	26.6	19.9	-3.6	6.5	23.7	42.0	12.2	13.8	10.5	22.2	17.7	
Interest	132	188	223	245	235	242	233	131	788	841	205	
Other Income	21	167	95	142	65	69	155	221	425	510	171	
<b>PBT before EO expense</b>	<b>1,567</b>	<b>1,667</b>	<b>1,774</b>	<b>1,926</b>	<b>1,905</b>	<b>2,223</b>	<b>2,056</b>	<b>2,400</b>	<b>6,934</b>	<b>8,584</b>	<b>2,204</b>	
Extra-Ord expense	0	-129	0	0	0	0	422	0	129	-422	0	
<b>PBT</b>	<b>1,567</b>	<b>1,796</b>	<b>1,774</b>	<b>1,926</b>	<b>1,905</b>	<b>2,223</b>	<b>1,633</b>	<b>2,400</b>	<b>7,063</b>	<b>8,161</b>	<b>2,204</b>	
Tax	225	273	401	353	365	532	295	432	1,252	1,624	399	
Rate (%)	14.4	15.2	22.6	18.3	19.1	23.9	18.1	18.0	17.7	19.9	18.1	
MI & P/L of Asso. Cos.	-5	-11	-11	4	-3	-24	8	11	-23	-8	9	
<b>Reported PAT</b>	<b>1,347</b>	<b>1,534</b>	<b>1,384</b>	<b>1,569</b>	<b>1,544</b>	<b>1,715</b>	<b>1,330</b>	<b>1,957</b>	<b>5,834</b>	<b>6,546</b>	<b>1,796</b>	
<b>Adj PAT</b>	<b>1,347</b>	<b>1,425</b>	<b>1,384</b>	<b>1,569</b>	<b>1,544</b>	<b>1,715</b>	<b>1,676</b>	<b>1,957</b>	<b>5,725</b>	<b>6,892</b>	<b>1,796</b>	<b>-6.7%</b>
YoY Change (%)	11.6	3.6	-23.5	-12.3	14.6	20.4	21.1	24.7	-7.2	20.4	29.7	
Margins (%)	8.6	8.6	8.2	8.9	9.0	9.0	8.9	10.3	8.6	9.3	9.7	
<b>EPS</b>	<b>6.9</b>	<b>7.2</b>	<b>7.0</b>	<b>8.0</b>	<b>7.9</b>	<b>8.7</b>	<b>8.5</b>	<b>10.0</b>	<b>29.1</b>	<b>35.1</b>	<b>9.1</b>	

E: MOFSL Estimates


### Key Performance Indicators (Consolidated)

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	
<b>India</b>	<b>5,720</b>	<b>6,090</b>	<b>6,140</b>	<b>5,450</b>	<b>5,990</b>	<b>6,390</b>	<b>6,530</b>	<b>5,923</b>	<b>23,400</b>	<b>24,833</b>	<b>6404</b>	
YoY Change (%)	9.2	5.5	3.0	8.3	4.7	4.9	6.4	8.7	6.4	6.1	4.3	
<b>Exports</b>	<b>7,320</b>	<b>7,650</b>	<b>8,200</b>	<b>8,830</b>	<b>8,510</b>	<b>9,580</b>	<b>9,590</b>	<b>9,730</b>	<b>32,000</b>	<b>37,410</b>	<b>9,204</b>	
YoY Change (%)	11.4	9.9	9.9	28.9	16.3	25.2	17.0	10.2	15.0	16.9	12.2	
<b>APIs</b>	<b>2,590</b>	<b>2,740</b>	<b>2,590</b>	<b>3,420</b>	<b>2,610</b>	<b>3,140</b>	<b>2,640</b>	<b>3,266</b>	<b>11,340</b>	<b>11,656</b>	<b>2,901</b>	
YoY Change (%)	(15.1)	(14.9)	(10.4)	3.6	0.8	14.6	1.9	(4.5)	(9.0)	2.8	12.0	
<b>Cost Break-up</b>												
RM Cost (% of Sales)	25.2	26.0	26.0	30.0	23.8	27.0	28.2	29.0	26.9	27.1	28.0	
Staff Cost (% of Sales)	24.3	23.8	23.5	22.2	24.7	22.9	23.1	22.4	23.4	23.2	22.2	
R&D Expenses (% of Sales)	7.0	8.0	7.0	9.1	8.5	9.8	8.8	8.0	7.8	8.8	8.3	
Other Cost (% of Sales)	28.3	27.7	28.2	23.3	26.5	23.8	24.3	24.1	26.8	24.6	25.1	
Gross Margins(%)	74.8	74.0	74.0	70.0	76.2	73.0	71.8	71.0	73.1	72.9	72.0	
EBITDA Margins(%)	15.2	14.5	15.4	15.4	16.4	16.5	15.6	16.5	15.1	16.3	16.4	
EBIT Margins(%)	10.7	10.2	11.2	11.5	12.1	12.5	11.4	12.2	10.9	12.1	12.1	

E: MOFSL Estimates


## Key exhibits

**Exhibit 1: DF sales grew 6.4% YoY in 3QFY26**




Source: MOFSL, Company

**Exhibit 2: International business grew 17% YoY in 3QFY26**




Source: MOFSL, Company

**Exhibit 3: Sales increased 10.8% YoY in 3QFY26**



Source: MOFSL, Company

**Exhibit 4: EBITDA margin expanded 30bp YoY in 3QFY26**



Source: MOFSL, Company



### Key highlights from the management commentary

- R&D spending was INR1.7b for 3QFY26.
- R&D spending to be 8-9% of sales in FY27.
- Injectables, peptides, and drug device combinations would be the areas of complex medicines, which ALPM would be focusing on in the US market.
- Filed 1ANDA/ received 7ANDA approvals / received 2 product launches in 3QFY26.
- ALPM plans to launch 4-5 products in 4QFY26.
- Net Working Capital stood at INR29.4b.
- Net Debt levels declined to INR12.1b as on 9MFY26.

## Exports to sustain the growth traction; DF growth to regain the momentum by 1QFY27

### US: product launches to drive generics growth

- The US sales grew 13%YoY/6%YoY in 9MFY26/3QFY26 to INR16.4b/INR5.5b, supported by new launches and driven by key product launches and market share gains in select therapies.
- ALPM launched nine products in 9MFY26, with a target of 4-5 launches in 4QFY26. While in 3QFY26, two products were launched.
- ALPM is strategically focused on evolving the portfolio and pipeline across complex platforms and specialty divisions. Further, the products from new facilities will contribute to the future growth.
- ALPM is on track to launch Pivya in 4QFY26, set to expand its footprint in branded drugs in the US.
- The approved portfolio stands at 232 ANDAs, comprising 156 oral solids, 31 dermatological, 22 ophthalmic, 21 injectable, and 2 inhalation products. Of these, 172 have been launched, implying a robust 74% commercialization rate.
- We expect the US business to deliver a 16% sales CAGR over FY25-28, reaching INR30.2b, driven by continued launch momentum and a healthy product pipeline.

### India: To realign with industry growth from 1QFY27


- DF business reported modest 5.3% YoY growth to INR18.9b in 9MFY26, largely driven by acute/animal health segments.
- Within the DF business specialty/acute/animal health segment grew 1.4%YoY/5.2%YoY/19.3%YoY to INR10b/INR5b/INR4b in 9MFY26.
- The specialty portfolio contributed 53% of DF revenue in 9MFY26. Within the segment, the therapies Gynaec (14%)/Cardiac (13%)/Gastro (10%)/Anti-Diabetic (6%) contributed to 43% of DF sales amounting to INR2.6b/2.4b/1.8b/1.2b.
- Amongst the top 4 contributors to the specialty segment, Gastro (decline of 11%YoY)/Anti-Diabetic (stable) dragged the growth. This was offset by 4%YoY/7%YoY growth in Cardiac/Gynaec for 9MFY26.
- In 9MFY26, the growth of 7%YoY in Gynaec therapy (the highest share contributor) was led by CRINA-NCR (+12%YoY)/GESTOFIT (+12%YoY)/ISOFIT (+8%YoY).
- For 9MFY26, the growth of 4%YoY in Cardiac therapy was driven by CETANIL(+15%YoY)/ROSAVE(+13%YoY) offset by a decline in TELLZY (-5%YoY).
- For 9MFY26, the stable growth in Anti-Diabetic therapy was led by GLISEN (-19%YoY)/VOAGE(-5%YoY)/GLIPY(-2%YoY) offset by momentum in SITALEMBIC (+25%YoY)/GLZ(+1%YoY).
- For 9MFY26, the decline of 11%YoY in Gastro therapy was led by DELTONE (-25%YoY)/REKOOL(-15%YoY)/ULGEL (-5%YoY).
- Within the acute portfolio, the therapies Anti-infective (18%)/Cardiac (9%) contributed 27% of DF revenue in 9MFY26, amounting to INR3.3b/INR1.7b.
- Animal Health reported 22%/19% YoY growth in 3QFY26/9MFY26, and a well-diversified product mix: antibiotic (10%), antiparasitic (10%), supportive therapy (18%), tonic (25%), feed supplement (37%).

- As per IQVIA, MAT Dec-25 IPM/ALPM grew 8.9%YoY/0.5% YoY. The stable growth was on account of a decline in volume growth of 6.1%YoY offset by price/new product launches growth of 4.9%YoY/1.7%YoY.
- ALPM launched 4/9 new brands in 3QFY26/9MFY26. The contribution of 2.4% of total branded sales for 9MFY26 was on account of recent launches.
- The gynecology, ophthalmology, and animal health segments continue to be the growth pillars.
- Prescription base stood at 135.2m over the past 12 months, up 5.5% YoY.
- We expect the India business to clock an 7.6% sales CAGR over FY25-28, reaching INR29.2b.

### Reiterate Neutral


- We largely maintain our estimates for FY26/FY27/FY28.
- While there have been considerable investments in the US generics space in terms of R&D as well as manufacturing capacity, it has yet to be reflected in meaningful revenue growth in this segment. The domestic formulation business is expected to gradually grow-in-line with the industry. Considering these factors and valuations adequately factoring in the earnings upside, we **reiterate our Neutral rating** with a TP of INR860.

Exhibit 5: P/E chart



Source: MOFSL, Company, Bloomberg


Exhibit 6: EV/EBITDA chart




Source: MOFSL, Company, Bloomberg

## Story in charts


**Exhibit 7: Formulation to post 11.2% CAGR over FY25-28**




**Exhibit 8: Expect DF to post a 7.6% CAGR over FY25-28**




**Exhibit 9: EBITDA CAGR to remain at 18.2% over FY25-28**




**Exhibit 10: R&D expenses to remain around 8-9% of sales**



**Exhibit 11: EBITDA margins to contract by 70bp over FY25-28**



**Exhibit 12: Earnings CAGR to remain at 22% over FY25-28**



## Financials and valuations

### Consolidated - Income Statement

	(INRm)						
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Net Sales</b>	<b>53,058</b>	<b>56,530</b>	<b>62,280</b>	<b>66,740</b>	<b>73,891</b>	<b>81,107</b>	<b>89,798</b>
Change (%)	-1.6	6.5	10.2	7.2	10.7	9.8	10.7
<b>EBITDA</b>	<b>9,972</b>	<b>8,198</b>	<b>9,327</b>	<b>10,102</b>	<b>12,027</b>	<b>14,022</b>	<b>16,686</b>
Change (%)	-36.0	-17.8	13.8	8.3	19.1	16.6	19.0
Margin (%)	18.8	14.5	15.0	15.1	16.3	17.3	18.6
Depreciation	2,218	2,314	2,727	2,786	3,112	3,470	3,805
<b>EBIT</b>	<b>7,754</b>	<b>5,884</b>	<b>6,601</b>	<b>7,316</b>	<b>8,916</b>	<b>10,552</b>	<b>12,881</b>
Int. and Finance Charges	177	502	562	788	841	798	792
Other Income - Rec.	505	27	283	425	510	710	710
<b>PBT bef. EO Exp.</b>	<b>8,081</b>	<b>5,409</b>	<b>6,322</b>	<b>6,953</b>	<b>8,584</b>	<b>10,464</b>	<b>12,799</b>
EO Expense/(Income)	1,880	1,550	0	-129	422	0	0
<b>PBT after EO Exp.</b>	<b>6,201</b>	<b>3,859</b>	<b>6,322</b>	<b>7,082</b>	<b>8,162</b>	<b>10,464</b>	<b>12,799</b>
Current Tax	1,279	42	658	1,629	1,877	2,407	2,944
Deferred Tax	-235	84	-498	-377	-253	-569	-624
Tax Rate (%)	16.8	3.3	2.5	17.7	19.9	17.6	18.1
MI & P/L of Asso. Cos.	-300.3	309.2	-9.8	-5.4	-8.0	72.0	76.0
<b>Reported PAT</b>	<b>5,457</b>	<b>3,424</b>	<b>6,172</b>	<b>5,836</b>	<b>6,546</b>	<b>8,554</b>	<b>10,404</b>
<b>PAT Adj for EO items</b>	<b>6,889</b>	<b>4,296</b>	<b>6,172</b>	<b>5,725</b>	<b>6,892</b>	<b>8,554</b>	<b>10,404</b>
Change (%)	-41.5	-37.6	43.7	-7.2	20.4	24.1	21.6
Margin (%)	13.0	7.6	9.9	8.6	9.3	10.5	11.6

### Consolidated - Balance Sheet

	(INRm)						
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	393	393	393	393	393	393	393
Total Reserves	51,982	43,312	47,789	51,516	56,871	64,314	73,611
Preference Capital	0	0	0	0	0	0	0
<b>Net Worth</b>	<b>52,375</b>	<b>43,705</b>	<b>48,182</b>	<b>51,909</b>	<b>57,265</b>	<b>64,707</b>	<b>74,004</b>
Minority Interest	0	0	0	-14	-14	-14	-14
Deferred Liabilities	0	0	0	189	-64	-633	-1,257
Total Loans	7,021	7,051	4,933	12,423	12,325	12,227	12,129
<b>Capital Employed</b>	<b>59,397</b>	<b>50,756</b>	<b>53,115</b>	<b>64,508</b>	<b>69,511</b>	<b>76,288</b>	<b>84,862</b>
Gross Block	27,221	35,532	39,741	42,295	50,973	55,801	61,280
Less: Accum. Deprn.	9,234	11,548	14,274	17,060	20,172	23,642	27,447
<b>Net Fixed Assets</b>	<b>17,987</b>	<b>23,985</b>	<b>25,467</b>	<b>25,235</b>	<b>30,801</b>	<b>32,159</b>	<b>33,833</b>
Capital WIP	23,034	6,013	5,244	8,372	3,695	4,866	5,388
<b>Total Investments</b>	<b>1,184</b>	<b>963</b>	<b>930</b>	<b>1,272</b>	<b>1,272</b>	<b>1,272</b>	<b>1,272</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>29,015</b>	<b>30,868</b>	<b>32,815</b>	<b>42,850</b>	<b>47,621</b>	<b>53,222</b>	<b>61,170</b>
Inventory	16,097	14,753	16,435	22,881	26,615	28,512	30,895
Account Receivables	8,071	10,464	10,248	13,998	14,981	15,777	17,222
Cash and Bank Balance	694	823	1,266	901	932	3,815	7,906
Loans and Advances	4,153	4,828	4,866	5,070	5,094	5,118	5,147
<b>Curr. Liability &amp; Prov.</b>	<b>11,824</b>	<b>11,073</b>	<b>11,341</b>	<b>13,222</b>	<b>13,878</b>	<b>15,232</b>	<b>16,801</b>
Account Payables	7,064	6,798	7,356	8,799	9,565	10,555	11,687
Other Current Liabilities	3,165	2,512	2,237	2,321	2,570	2,821	3,123
Provisions	1,595	1,763	1,748	2,102	1,743	1,856	1,992
<b>Net Current Assets</b>	<b>17,192</b>	<b>19,795</b>	<b>21,474</b>	<b>29,628</b>	<b>33,743</b>	<b>37,990</b>	<b>44,369</b>
Misc Expenditure	0	0	0	0	0	0	0
<b>Appl. of Funds</b>	<b>59,397</b>	<b>50,756</b>	<b>53,115</b>	<b>64,508</b>	<b>69,511</b>	<b>76,288</b>	<b>84,862</b>



## Financials and valuations

### Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>							
<b>EPS</b>	<b>35.0</b>	<b>21.9</b>	<b>31.4</b>	<b>29.1</b>	<b>35.1</b>	<b>43.5</b>	<b>52.9</b>
Cash EPS	46.3	33.6	45.3	43.3	50.9	61.2	72.3
BV/Share	266.5	222.4	245.1	264.1	291.3	329.2	376.5
DPS	10.4	4.2	5.2	5.2	5.2	5.2	5.2
Payout (%)	43.4	27.6	19.2	20.3	18.1	13.8	11.4
<b>Valuation (x)</b>							
P/E	22.9	36.7	25.5	27.5	22.9	18.4	15.2
Cash P/E	17.3	23.9	17.7	18.5	15.8	13.1	11.1
P/BV	3.0	3.6	3.3	3.0	2.8	2.4	2.1
EV/Sales	3.7	3.5	3.1	3.0	2.7	2.4	2.2
EV/EBITDA	19.7	23.9	20.7	19.9	16.7	14.1	11.6
Dividend Yield (%)	1.3	0.5	0.7	0.7	0.7	0.7	0.7
<b>Return Ratios (%)</b>							
RoE	13.9	8.3	13.5	11.5	12.6	13.9	14.9
RoCE	12.1	10.4	12.9	10.9	11.3	12.7	13.6
RoIC	20.6	14.7	14.5	12.1	12.1	13.4	15.4
<b>Working Capital Ratios</b>							
Asset Turnover (x)	0.9	1.1	1.2	1.0	1.1	1.1	1.1
Inventory (Days)	111	95	96	125	131	128	126
Debtor (Days)	56	68	60	77	74	71	70
Creditor (Days)	49	44	43	48	47	48	48
<b>Leverage Ratio (x)</b>							
Net Debt/Equity	0.1	0.1	0.1	0.2	0.2	0.1	0.1

### Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>(INRm)</b>							
Net Profit / (Loss) Before Tax	6,201	3,546	6,318	7,072	8,162	10,464	12,799
Depreciation	2,868	2,754	2,727	2,786	3,112	3,470	3,805
Interest & Finance Charges	131	502	562	788	331	88	82
Direct Taxes Paid	1,234	607	199	714	1,877	2,407	2,944
(Inc)/Dec in WC	-3,673	-576	-957	-9,214	-4,084	-1,363	-2,289
<b>CF from Operations</b>	<b>4,292</b>	<b>5,619</b>	<b>8,452</b>	<b>718</b>	<b>5,644</b>	<b>10,252</b>	<b>11,453</b>
Others	1,231	1,620	-819	383	0	0	0
<b>CF from Operating incl EO</b>	<b>5,524</b>	<b>7,239</b>	<b>7,633</b>	<b>1,101</b>	<b>5,644</b>	<b>10,252</b>	<b>11,453</b>
(inc)/dec in FA	-4,243	-4,434	-3,159	-5,539	-4,000	-6,000	-6,000
<b>Free Cash Flow</b>	<b>1,281</b>	<b>2,805</b>	<b>4,474</b>	<b>-4,437</b>	<b>1,644</b>	<b>4,252</b>	<b>5,453</b>
(Pur)/Sale of Investments	523	-64	-63	55	0	0	0
Others	17	22	32	-146	510	710	710
<b>CF from Investments</b>	<b>-3,702</b>	<b>-4,476</b>	<b>-3,190</b>	<b>-5,629</b>	<b>-3,490</b>	<b>-5,290</b>	<b>-5,290</b>
Issue of Shares	0	0	0	0	0	0	0
(Inc)/Dec in Debt	1,300	-172	-2,312	7,385	-98	-98	-98
Interest Paid	-519	-497	-494	-786	-841	-798	-792
Dividend Paid	-2,752	-1,966	-1,573	-2,162	-1,183	-1,183	-1,183
<b>CF from Fin. Activity</b>	<b>-2,186</b>	<b>-2,635</b>	<b>-4,379</b>	<b>4,437</b>	<b>-2,122</b>	<b>-2,079</b>	<b>-2,072</b>
<b>Inc/Dec of Cash</b>	<b>-364</b>	<b>129</b>	<b>64</b>	<b>-91</b>	<b>31</b>	<b>2,883</b>	<b>4,091</b>
Add: Beginning Balance	1,059	694	823	1,266	901	932	3,815
<b>Closing Balance</b>	<b>694</b>	<b>823</b>	<b>887</b>	<b>1,175</b>	<b>932</b>	<b>3,815</b>	<b>7,906</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/Publish/ViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.raiani@motilaloswal.com](mailto:nainesh.raiani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: No.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors  
Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,  
Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579, APML: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.